Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generational effects in Down syndrome, Enriched environment enhances functionality without reducing Alzheimer's disease risk

  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Lleó, Alberto|||0000-0002-2568-5478
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis. We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta-analysis. Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID-related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years. The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis. OrderedDict([(u'list', OrderedDict([(u'@list-type', u'bullet'), (u'@id', u'alz70447-list-0001'), (u'list-item', [OrderedDict([(u'p', u'A generational effect has reduced the severity of intellectual disability in Down syndrome (DS).')]), OrderedDict([(u'p', u'Individuals with DS have increased autonomy and improved intellectual milestones.')]), OrderedDict([(u'p', u"The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS.")]), OrderedDict([(u'p', u'Further studies should confirm if cognitive reserve might delay AD in DS.'.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI

  • Aranha, Mateus Rozalem
  • González-Ortiz, Sofía
  • Fortea, Juan
Background: Cortical microinfarcts (CMI) were attributed to cerebrovascular disease and cerebral amyloid angiopathy (CAA). CAA is frequent in Down syndrome (DS) while hypertension is rare, yet no studies have assessed CMI in DS. Methods: We included 195 adults with DS, 63 with symptomatic sporadic Alzheimer's disease (AD), and 106 controls with 3T magnetic resonance imaging. We assessed CMI prevalence in each group and CMI association with age, AD clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition in DS. Results: CMI prevalence was 11.8% in DS, 4.7% in controls, and 17.5% in sporadic AD. In DS, CMI increased in prevalence with age and the AD clinical continuum, was clustered in the parietal lobes, and was associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. Discussion: In DS, CMI are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic CAA phenotype. Highlights: This is the first study to assess cortical microinfarcts (assessed with 3T magnetic resonance imaging) in adults with Down syndrome (DS). We studied the prevalence of cortical microinfarcts in DS and its relationship with age, the Alzheimer's disease (AD) clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition. The prevalence of cortical microinfarcts was 11.8% in DS and increased with age and along the AD clinical continuum. Cortical microinfarcts were clustered in the parietal lobes, and were associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, cortical microinfarcts are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic phenotype of cerebral amyloid angiopathy., This study was funded by Alzheimer's Association Research Fellowship to Promote Diversity (AARF-D) Program (AARFD-21-852492) to MRA. It was also supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute (co-funded by European Regional Development Fund/European Social Fund - A way to make Europe / Investing in your future) (PI20/01473 to JF, PI13/01532, PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 to DA, PI14/1561, PI20/01330 to AL, PI22/00307 to AB), the CIBERNED Program 1, the National Institutes of Health (NIH) (1R01AG056850-01A1; 3RF1AG056850-01S1; AG056850, R21AG056974, and R01AG061566 to JF), the Departament de Salut de la Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to JF), the European Union's Horizon 2020, “MES-CoBraD” (H2020-SC1-BHC-2018-2020 / GA 965422 to JF), Brightfocus, and Life Molecular Imaging (LMI) to JF. AB acknowledges support from a Miguel Servet grant (CP20/00038) from the Carlos III Health Institute. and the Alzheimer's Association (AARG-22-923680). MCI acknowledges support from the Alzheimer's Association and Global Brain Health Institute (GBHI_ALZ-18-543740), the Jérôme Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020). VM acknowledges support from Predoctoral grants from the Carlos III Health Institute (FI18/00275). JA was supported by the Río Hortega Fellowship from Carlos III Health Institute (CM21/00243). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit for publication.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Generational effects in Down syndrome: enriched environment enhances functionality without reducing Alzheimer's disease risk

  • Vaqué-Alcázar, Lídia
  • Videla, Laura
  • Benejam, Bessy
  • Del Hoyo Soriano, Laura
  • Barroeta, Isabel
  • Fernandez, Susana
  • Rodríguez-Baz, Íñigo
  • Arriola-Infante, José Enrique
  • Arranz, Javier
  • Maure Blesa, Lucía
  • Sanjuan-Hernández, Aida
  • Morcillo-Nieto, Alejandra O.
  • Bejanin, Alexandre
  • Arenaza Urquijo, Eider M.
  • Lleó, Alberto
  • Bartrés-Faz, David
  • Carmona Iragui, María
  • Fortea, Juan
Introduction: Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis. Methods: We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta-analysis. Results: Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID-related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years. Discussion: The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis. Highlights: A generational effect has reduced the severity of intellectual disability in Down syndrome (DS). Individuals with DS have increased autonomy and improved intellectual milestones. The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS. Further studies should confirm if cognitive reserve might delay AD in DS., This study was funded by the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III and co-funded by the European Union (PI18/00335 and PI22/00785 to M.C.I., PI22/00307 to A.B., PI14/1561, PI20/01330 to A.L., PI20/01473 and PI23/01786 to J.F.), the CIBERNED Program 1, the National Institutes of Health (NIH; 1R01AG056850-01A1; 3RF1AG056850-01S1; AG056850, R21AG056974, and R01AG061566 to J.F.), the Departament de Salut de la Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to J.F.), the European Union's Horizon 2020, “MES-CoBraD” (H2020-SC1-BHC-2018-2020 / GA 965422 to J.F.), Brightfocus, and Life Molecular Imaging (LMI) to J.F. L.V.A. was supported by Instituto de Salud Carlos III through the Sara Borrell Postdoctoral Fellowship “CD23/00235.” M.C.I. acknowledges support from the Alzheimer's Association (AARG-22-973966) and Global Brain Health Institute (GBHI_ALZ-18-543740), the Jérôme Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020). I.R.B. was supported by Instituto de Salud Carlos III through the Río Hortega Fellowship “CM22/00052” and co-funded by the European Union. J.E.A.I. was supported by Instituto de Salud Carlos III through the Río Hortega Fellowship “CM22/00219” and co-funded by the European Union. L.M.B. was supported by Instituto de Salud Carlos III through the Río Hortega Fellowship “CM23/00291” and co-funded by the European Union. A.B. acknowledges support from Instituto de Salud Carlos III through the Miguel Servet grant “CP20/00038” and co-funded by the European Union and the Alzheimer's Association “AARG-22-923680”. L.D.H.S. acknowledges support from Instituto de Salud Carlos III through the Miguel Servet grant “CP24/00112” and co-funded by the European Union and the Jérôme Lejeune Foundation (2326 - GRT-2024A). D.B.F. was supported by funds of the ICREA Academia program (2019 and 2024). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit for publication.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome

  • Aranha, Mateus Rozalem
  • Iulita, Maria Florencia
  • Montal, Victor
  • Pegueroles, Jordi
  • Bejanin, Alexandre
  • Vaqué-Alcázar, Lídia
  • Grothe, Michel J.
  • Carmona-Iragui, Maria
  • Videla, Laura
  • Benejam, Bessy
  • Arranz, Javier
  • Padilla, Concepción
  • Valldeneu, Sílvia
  • Barroeta, Isabel
  • Altuna, Miren
  • Fernández, Susana
  • Ribas, Laia
  • Valle-Tamayo, Natalia
  • Alcolea, Daniel
  • González-Ortiz, Sofía
  • Bargalló, Núria
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Blesa, Rafael
  • Wisniewski, Thomas
  • Busciglio, Jorge
  • Cuello, A. Claudio
  • Lleó, Alberto
  • Fortea, Juan
[Background] Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS., [Methods] We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume., [Results] In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance., [Discussion] BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS., This study was supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute (PI20/01473 to JF, PI13/01532, PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 to DA, PI14/1561, PI20/01330 to AL, PI20/00613 to MJG) and the CIBERNED Program 1. This work was also supported by the National Institutes of Health (NIH) grants (1R01AG056850-01A1; 3RF1AG056850-01S1; AG056850, R21AG056974, and R01AG061566 to JF; P30AG066512 and P01AG060882 to TW), Departament de Salut de la Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to JF), and the European Union's Horizon 2020, ‘MES-CoBraD’ (H2020-SC1-BHC-2018-2020 / GA 965422 to JF). MRA acknowledges support from the Alzheimer's Association Research Fellowship to Promote Diversity (AARF-D) Program (AARFD-21-852492). MFI acknowledges support from the Jérôme Lejeune postdoctoral award and pilot grant (#1941). AB acknowledges support from a Miguel Servet grant (CP20/00038) from the Carlos III Health Institute. MJG acknowledges support from a Miguel Servet grant (CP19/00031) from the Carlos III Health Institute. MCI acknowledges support from the Alzheimer's Association and Global Brain Health Institute (GBHI_ALZ-18-543740), the Jérôme Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020). LVA was supported by Margarita Salas junior postdoctoral fellowship (UNI/551/2021, NextGenerationUE). VM and NVT acknowledge support from predoctoral grants from the Carlos III Health Institute (FI18/00275 to VM and FI22/00077 to NVT). MA and JA were supported by the Río Hortega Fellowship from Carlos III Health Institute (CM19/00066 to MA and CM21/00243 to JA). CP acknowledges support from a Sara Borrell Fellowship (CP20/00133) from the Carlos III Health Institute. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), and the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI

  • Aranha, Mateus Rozalem
  • González-Ortiz, Sofía
  • Fortea, Juan
Background: Cortical microinfarcts (CMI) were attributed to cerebrovascular disease and cerebral amyloid angiopathy (CAA). CAA is frequent in Down syndrome (DS) while hypertension is rare, yet no studies have assessed CMI in DS. Methods: We included 195 adults with DS, 63 with symptomatic sporadic Alzheimer's disease (AD), and 106 controls with 3T magnetic resonance imaging. We assessed CMI prevalence in each group and CMI association with age, AD clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition in DS. Results: CMI prevalence was 11.8% in DS, 4.7% in controls, and 17.5% in sporadic AD. In DS, CMI increased in prevalence with age and the AD clinical continuum, was clustered in the parietal lobes, and was associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. Discussion: In DS, CMI are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic CAA phenotype. Highlights: This is the first study to assess cortical microinfarcts (assessed with 3T magnetic resonance imaging) in adults with Down syndrome (DS). We studied the prevalence of cortical microinfarcts in DS and its relationship with age, the Alzheimer's disease (AD) clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition. The prevalence of cortical microinfarcts was 11.8% in DS and increased with age and along the AD clinical continuum. Cortical microinfarcts were clustered in the parietal lobes, and were associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, cortical microinfarcts are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic phenotype of cerebral amyloid angiopathy., This study was funded by Alzheimer's Association Research Fellowship to Promote Diversity (AARF-D) Program (AARFD-21-852492) to MRA. It was also supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute (co-funded by European Regional Development Fund/European Social Fund - A way to make Europe / Investing in your future) (PI20/01473 to JF, PI13/01532, PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 to DA, PI14/1561, PI20/01330 to AL, PI22/00307 to AB), the CIBERNED Program 1, the National Institutes of Health (NIH) (1R01AG056850-01A1; 3RF1AG056850-01S1; AG056850, R21AG056974, and R01AG061566 to JF), the Departament de Salut de la Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to JF), the European Union's Horizon 2020, “MES-CoBraD” (H2020-SC1-BHC-2018-2020 / GA 965422 to JF), Brightfocus, and Life Molecular Imaging (LMI) to JF. AB acknowledges support from a Miguel Servet grant (CP20/00038) from the Carlos III Health Institute. and the Alzheimer's Association (AARG-22-923680). MCI acknowledges support from the Alzheimer's Association and Global Brain Health Institute (GBHI_ALZ-18-543740), the Jérôme Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020). VM acknowledges support from Predoctoral grants from the Carlos III Health Institute (FI18/00275). JA was supported by the Río Hortega Fellowship from Carlos III Health Institute (CM21/00243). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Generational effects in Down syndrome: enriched environment enhances functionality without reducing Alzheimer's disease risk

  • Vaqué-Alcázar, Lídia
  • Videla, Laura
  • Benejam, Bessy
  • Del Hoyo Soriano, Laura
  • Barroeta, Isabel
  • Fernandez, Susana
  • Rodríguez-Baz, Íñigo
  • Arriola-Infante, José Enrique
  • Arranz, Javier
  • Maure Blesa, Lucía
  • Sanjuan-Hernández, Aida
  • Morcillo-Nieto, Alejandra O.
  • Bejanin, Alexandre
  • Arenaza Urquijo, Eider M.
  • Lleó, Alberto
  • Bartrés-Faz, David
  • Carmona Iragui, María
  • Fortea, Juan
Introduction: Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis. Methods: We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta-analysis. Results: Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID-related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years. Discussion: The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis. Highlights: A generational effect has reduced the severity of intellectual disability in Down syndrome (DS). Individuals with DS have increased autonomy and improved intellectual milestones. The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS. Further studies should confirm if cognitive reserve might delay AD in DS., This study was funded by the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III and co-funded by the European Union (PI18/00335 and PI22/00785 to M.C.I., PI22/00307 to A.B., PI14/1561, PI20/01330 to A.L., PI20/01473 and PI23/01786 to J.F.), the CIBERNED Program 1, the National Institutes of Health (NIH; 1R01AG056850-01A1; 3RF1AG056850-01S1; AG056850, R21AG056974, and R01AG061566 to J.F.), the Departament de Salut de la Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to J.F.), the European Union's Horizon 2020, “MES-CoBraD” (H2020-SC1-BHC-2018-2020 / GA 965422 to J.F.), Brightfocus, and Life Molecular Imaging (LMI) to J.F. L.V.A. was supported by Instituto de Salud Carlos III through the Sara Borrell Postdoctoral Fellowship “CD23/00235.” M.C.I. acknowledges support from the Alzheimer's Association (AARG-22-973966) and Global Brain Health Institute (GBHI_ALZ-18-543740), the Jérôme Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020). I.R.B. was supported by Instituto de Salud Carlos III through the Río Hortega Fellowship “CM22/00052” and co-funded by the European Union. J.E.A.I. was supported by Instituto de Salud Carlos III through the Río Hortega Fellowship “CM22/00219” and co-funded by the European Union. L.M.B. was supported by Instituto de Salud Carlos III through the Río Hortega Fellowship “CM23/00291” and co-funded by the European Union. A.B. acknowledges support from Instituto de Salud Carlos III through the Miguel Servet grant “CP20/00038” and co-funded by the European Union and the Alzheimer's Association “AARG-22-923680”. L.D.H.S. acknowledges support from Instituto de Salud Carlos III through the Miguel Servet grant “CP24/00112” and co-funded by the European Union and the Jérôme Lejeune Foundation (2326 - GRT-2024A). D.B.F. was supported by funds of the ICREA Academia program (2019 and 2024). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit for publication.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Olmedo-Saura, Gonzalo|||0000-0003-4864-5548
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Epilepsy and Alzheimer's disease (AD) incidence increases with age. There are recip-rocal relationships between epilepsy and AD. Epilepsy is a risk factor for AD and, in turn, AD is an independent risk factor for developing epilepsy in old age, and abnormal AD biomarkers in PET and/or CSF are frequently found in late-onset epilepsies of unknown etiology. Accordingly, epilepsy and AD share pathophysiological processes, including neuronal hyperexcitability and an early excitatory-inhibitory dysregulation, leading to dysfunction in the inhibitory GABAergic and excitatory glutamatergic systems. Moreover, both β-amyloid and tau protein aggregates, the anato-mopathological hallmarks of AD, have proepileptic effects. Finally, these aggregates have been found in the resection material of refractory temporal lobe epilepsies, suggesting that epilepsy leads to amyloid and tau aggregates. Some epileptic syndromes, such as medial temporal lobe epilepsy, share structural and functional neuroimaging findings with AD, leading to overlapping symptomatology, such as episodic memory deficits and toxic synergistic effects. In this respect, the existence of epilepti-form activity and electroclinical seizures in AD appears to accelerate the progression of cognitive decline, and the presence of cognitive decline is much more prevalent in epileptic patients than in elderly patients without epilepsy. Notwithstanding their clinical significance, the diagnosis of clinical seizures in AD is a challenge. Most are focal and manifest with an altered level of consciousness without motor symptoms, and are often interpreted as cognitive fluctuations. Finally, despite the frequent association of epilepsy and AD dementia, there is a lack of clinical trials to guide the use of antiseizure medications (ASMs). There is also a potential role for ASMs to be used as disease-modifying drugs in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cortical microstructure in primary progressive aphasia, a multicenter study

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Mandelli, Maria Luisa|||0000-0002-2518-2520
  • Falgàs, Neus|||0000-0002-3404-2765
  • Welch, Ariane E.
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Blesa, Rafael|||0000-0003-4026-2884
  • Dickerson, Bradford C.
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Lleó, Alberto|||0000-0002-2568-5478
  • Gorno-Tempini, Maria Luisa
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. We aimed to test the hypothesis that cortical mean diffusivity is more sensitive than cortical thickness to detect cortical changes in primary progressive aphasia (PPA). Methods: In this multicenter, case-control study, we recruited 120 patients with PPA (52 non-fluent, 31 semantic, and 32 logopenic variants; and 5 GRN-related PPA) as well as 89 controls from three centers. The 3-Tesla MRI protocol included structural and diffusion-weighted sequences. Disease severity was assessed with the Clinical Dementia Rating scale. Cortical thickness and cortical mean diffusivity were computed using a surface-based approach. Results: The comparison between each PPA variant and controls revealed cortical mean diffusivity increases and cortical thinning in overlapping regions, reflecting the canonical loci of neurodegeneration of each variant. Importantly, cortical mean diffusivity increases also expanded to other PPA-related areas and correlated with disease severity in all PPA groups. Cortical mean diffusivity was also increased in patients with very mild PPA when only minimal cortical thinning was observed and showed a good correlation with measures of disease severity. Conclusions: Cortical mean diffusivity shows promise as a sensitive biomarker for the study of the neurodegeneration-related microstructural changes in PPA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome

  • Aranha, Mateus|||0000-0001-9594-292X
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Grothe, Michel|||0000-0003-2600-9022
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Alcolea, Daniel|||0000-0002-3819-3245
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Wisniewski, Thomas M.
  • Busciglio, Jorge A.
  • Cuello, AC.|||0000-0003-2143-2745
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS. Methods: We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume. Results: In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance. Discussion: BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS.